Lynn Shemanski

Lynn has over 30 years of biostatistical experience in clinical trial design and analysis. She has been Director of Biometrics at drug companies and CROs, thereby bringing a unique understanding of both Sponsor and CRO outlooks. Dr. Shemanski’s biostatistical experience spans early to late phase clinical trials and has resulted in several successful new drug applications. Dr. Shemanski’s industry experience includes director positions at Zymogenetics (a subsidiary of Bristol Meyers Squibb) and Axio Research (a CRO subsidiary of Cytel). She has served as both Independent (reporting) and DSMB statistician on several clinical trials throughout her career. To date, she has worked on over 100 clinical trials across a wide spectrum of clinical indications.